[go: up one dir, main page]

ES521370A0 - A PROCEDURE FOR OBTAINING A POLYDOMA. - Google Patents

A PROCEDURE FOR OBTAINING A POLYDOMA.

Info

Publication number
ES521370A0
ES521370A0 ES521370A ES521370A ES521370A0 ES 521370 A0 ES521370 A0 ES 521370A0 ES 521370 A ES521370 A ES 521370A ES 521370 A ES521370 A ES 521370A ES 521370 A0 ES521370 A0 ES 521370A0
Authority
ES
Spain
Prior art keywords
polydoma
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES521370A
Other languages
Spanish (es)
Other versions
ES8504461A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES521370A0 publication Critical patent/ES521370A0/en
Publication of ES8504461A1 publication Critical patent/ES8504461A1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES521370A 1982-04-12 1983-04-11 Antibodies having dual specificities, their preparation and uses therefor. Expired ES8504461A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES521370A0 true ES521370A0 (en) 1985-04-16
ES8504461A1 ES8504461A1 (en) 1985-04-16

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (en) 1982-04-12 1983-04-11 Antibodies having dual specificities, their preparation and uses therefor.
ES527963A Expired ES8503441A1 (en) 1982-04-12 1983-12-12 Antibodies having dual specificities, their preparation and uses therefor.
ES533930A Granted ES533930A0 (en) 1982-04-12 1984-07-02 A PROCEDURE FOR OBTAINING A POLYDOMA
ES533931A Expired ES8506091A1 (en) 1982-04-12 1984-07-02 A PROCEDURE FOR OBTAINING A POLYDOMA
ES537257A Expired ES8606655A1 (en) 1982-04-12 1984-10-31 Antibodies having dual specificities, their preparation and uses therefor.
ES538727A Expired ES8604424A1 (en) 1982-04-12 1984-12-18 A PROCEDURE TO OBTAIN A SELECTIVELY DESTRUCTIBLE HYBRIDOMA (AS A DIVISIONAL OF THE INVENTION PATENT APPLICATION NUM 521370 FILED APRIL 11, 1983
ES545247A Expired ES8607386A1 (en) 1982-04-12 1985-07-16 Antibodies having dual specificities, their preparation and uses therefor.

Family Applications After (6)

Application Number Title Priority Date Filing Date
ES527963A Expired ES8503441A1 (en) 1982-04-12 1983-12-12 Antibodies having dual specificities, their preparation and uses therefor.
ES533930A Granted ES533930A0 (en) 1982-04-12 1984-07-02 A PROCEDURE FOR OBTAINING A POLYDOMA
ES533931A Expired ES8506091A1 (en) 1982-04-12 1984-07-02 A PROCEDURE FOR OBTAINING A POLYDOMA
ES537257A Expired ES8606655A1 (en) 1982-04-12 1984-10-31 Antibodies having dual specificities, their preparation and uses therefor.
ES538727A Expired ES8604424A1 (en) 1982-04-12 1984-12-18 A PROCEDURE TO OBTAIN A SELECTIVELY DESTRUCTIBLE HYBRIDOMA (AS A DIVISIONAL OF THE INVENTION PATENT APPLICATION NUM 521370 FILED APRIL 11, 1983
ES545247A Expired ES8607386A1 (en) 1982-04-12 1985-07-16 Antibodies having dual specificities, their preparation and uses therefor.

Country Status (11)

Country Link
EP (1) EP0105360A4 (en)
JP (2) JPH0753119B2 (en)
AT (1) AT394577B (en)
AU (1) AU550486B2 (en)
CA (1) CA1213229A (en)
CH (1) CH672796A5 (en)
ES (7) ES8504461A1 (en)
FI (2) FI900212A0 (en)
GB (4) GB2128631B (en)
IT (1) IT1219778B (en)
WO (1) WO1983003679A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (en) * 1988-09-27 2001-06-18 武田薬品工業株式会社 Hybrid monoclonal antibodies, antibody-producing polydomas and antibody-containing drugs
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1214123A (en) * 1983-01-20 1986-11-18 Masashi Matsui Cell lines for use in the preparation of hybridoma cells
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0179872B1 (en) * 1984-04-23 1991-06-19 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
NL8501219A (en) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic IMMUNOLOGICAL COMPLEX, ITS PREPARATION AND APPLICATION.
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
EP0241907A3 (en) 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
FR2604092B1 (en) * 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
ATE108068T1 (en) * 1987-09-23 1994-07-15 Bristol Myers Squibb Co ANTIBODY HETEROCONJUGATES FOR KILLING HIV-INFECTED CELLS.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
JPH02196799A (en) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol Complex of anti-human cancer protein
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (en) * 1988-12-23 1992-06-30 Biodata Spa IMMUNOLOGICAL TEST FOR HOMOGENEOUS DETERMINATIONS
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (en) * 1989-09-21 1994-10-28 Immunotech Partners NOVEL HYDROPHILIC DERIVATIVES, APPLICATION TO DIAGNOSIS AND THERAPEUTICS, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS.
CA2075927A1 (en) * 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (en) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
EP0582595A1 (en) * 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
AU741338B2 (en) * 1996-09-20 2001-11-29 Bristol-Myers Squibb Company Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
PT2357006E (en) 2002-07-31 2016-01-22 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT1725249E (en) 2003-11-06 2014-04-10 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7932242B2 (en) 2004-03-16 2011-04-26 Temple University - Of The Commonwealth System Of Higher Education Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
JP2008519863A (en) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Auristatin having an aminobenzoic acid unit at the N-terminus
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
EP1912671B1 (en) 2005-07-18 2017-09-06 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
ES2426158T3 (en) 2007-01-22 2013-10-21 Genentech, Inc. Precipitation with polyelectrolyte and antibody purification
PL2282773T3 (en) 2008-05-02 2014-08-29 Seattle Genetics Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN105358174B (en) 2013-03-15 2019-03-15 酵活有限公司 Cytotoxic and antimitotic compounds and methods for their use
WO2015053381A1 (en) * 2013-10-10 2015-04-16 幸成 加藤 Anti-podoplanin antibody
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
RS62860B1 (en) 2014-09-17 2022-02-28 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3165532B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Auristatin derivatives, linker-drugs and ligand-drug conjugates
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
SG11201908325PA (en) 2017-03-24 2019-10-30 Seattle Genetics Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
EP3847195B1 (en) * 2018-08-30 2025-03-05 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
PH12021552853A1 (en) 2019-05-10 2022-10-24 Takeda Pharmaceuticals Co Antibody drug conjugates
TWI877278B (en) 2019-12-30 2025-03-21 美商思進公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
IL309405A (en) 2021-06-29 2024-02-01 Seagen Inc Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
GB2168998A (en) 1986-07-02
ES545247A0 (en) 1986-05-16
AT394577B (en) 1992-05-11
GB2167086B (en) 1987-03-04
ES8606655A1 (en) 1986-04-01
JPS6312276A (en) 1988-01-19
ES8607386A1 (en) 1986-05-16
JPH0753119B2 (en) 1995-06-07
ES8603080A1 (en) 1985-12-01
ES533930A0 (en) 1985-12-01
ES527963A0 (en) 1985-02-16
JPH0753600A (en) 1995-02-28
ES8604424A1 (en) 1986-02-01
GB8530308D0 (en) 1986-01-22
GB2128631A (en) 1984-05-02
IT1219778B (en) 1990-05-24
GB2167086A (en) 1986-05-21
GB8530310D0 (en) 1986-01-22
AU550486B2 (en) 1986-03-20
GB2169921A (en) 1986-07-23
FI900212A7 (en) 1990-01-15
CH672796A5 (en) 1989-12-29
ATA901883A (en) 1991-10-15
ES533931A0 (en) 1985-06-16
GB8332646D0 (en) 1984-01-11
GB8530309D0 (en) 1986-01-22
FI834529A7 (en) 1983-12-09
ES538727A0 (en) 1986-02-01
AU1555983A (en) 1983-11-04
ES8504461A1 (en) 1985-04-16
GB2168998B (en) 1987-03-04
ES537257A0 (en) 1986-04-01
WO1983003679A1 (en) 1983-10-27
EP0105360A1 (en) 1984-04-18
JP2562002B2 (en) 1996-12-11
ES8506091A1 (en) 1985-06-16
GB2169921B (en) 1987-03-04
GB2128631B (en) 1987-02-25
FI900212A0 (en) 1990-01-15
ES8503441A1 (en) 1985-02-16
FI834529L (en) 1983-12-09
EP0105360A4 (en) 1986-07-08
IT8320548A0 (en) 1983-04-12
CA1213229A (en) 1986-10-28
FI834529A0 (en) 1983-12-09

Similar Documents

Publication Publication Date Title
ES521370A0 (en) A PROCEDURE FOR OBTAINING A POLYDOMA.
ES519925A0 (en) A PROCEDURE FOR FORMING AN ABSORBENT MATERIAL.
ES534203A0 (en) A PROCEDURE FOR PREPARING NEW CEFEM COMPOUNDS.
ES523195A0 (en) A PROCEDURE FOR PREPARING ALKYL-GLYCOSIDES
ES537668A0 (en) A PROCEDURE FOR PREPARING N-FORMIL-3-PHENOXI-1-AZETIDINCARBOXAMIDES
ES523064A0 (en) PROCEDURE FOR PREPARING AZETIDINS.
ES519652A0 (en) A PROCEDURE FOR OBTAINING S-ADENOSIL-METIONINE.
AR231308A1 (en) A PROCEDURE FOR PREPARING 1-BE-D-RIBOFURANOSIL-1,2,4-TRIAZOLCARBOXAMIDE RIVAVIRINE
ES520364A0 (en) A PROCEDURE FOR PREPARING CEFEM COMPOUNDS.
FI73942B (en) A UTLOESARE MANOEVRERBAR FOERDELNINGSVENTIL FOER EN UNDER TRYCK STAOENDE BEHAOLLARE.
ES523193A0 (en) A PROCEDURE FOR PREPARING 3-PHENOXI-1-AZETIDINCARBO-XZNMIDAS
ES518758A0 (en) A PROCEDURE FOR PREPARING AZETIDINS.
ES538192A0 (en) A PROCEDURE FOR PREPARING A 2-JOKE-6B-9A - DIFLUORO-11B, 17A, 21-TRIHIDROXI-1, 4-PREGNADIEN-3, 20-DIONA-17, 21-DIESTER
ES521813A0 (en) PROCEDURE FOR PREPARING ALCOHYL-POLYSACCHARIDES.
ES520531A0 (en) PROCEDURE FOR PREPARING TIOETERES.
ES519936A0 (en) A PROCEDURE FOR PREPARING PIRIMIDONE DERIVATIVES.
ES527278A0 (en) A PROCEDURE FOR OBTAINING 2,5-ANHYDRO-3,4,6-TRI-O-ACIL-D-ALONSELENOCARBOXAMIDE
ES524772A0 (en) A PROCEDURE FOR PREPARING PHENYLANILINS-N. SUBSTITUTED.
ES522716A0 (en) A PROCEDURE FOR PREPARING A PIRAZOLE DERIVATIVE.
ES523277A0 (en) A PROCEDURE FOR PREPARING PEPTIDES.
ES527108A0 (en) A PROCEDURE FOR PREPARING 2-ALCOXY-5- (PIRIDINIL) PIRIDINAS
NO157221C (en) ELECTROPLETING PROCEDURE.
ES520370A0 (en) A PROCEDURE FOR OBTAINING ISOXAZOLOPYRIMIDINE DERIVATIVES.
ES520879A0 (en) A PROCEDURE FOR PREPARING 1-HYDROXYETHYL-1H-TETRAZOLE-5-THYOL OPTIONALLY PROTECTED.
ES527247A0 (en) A PROCEDURE FOR OBTAINING CEMENT-CONCRETE

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401